cancer is the leading cause of cancer-related mor-tality worldwide.1Non-small cell lung cancer (NSCLC) isthe most common form, and many patients present withadvanced disease at initial diagnosis. Platinum-based dou-blet chemotherapy is still the standard therapy for NSCLC.However, the response rate of chemotherapy is only 20—35%,and median overall survival is about 6.9—11.3 months.2,3Recent